Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brandon Tibbitts

Physician Assistant Wethersfield, CT Physician Assistant

NPI 1205276474 CMS profile 5145842

1290 Silas Deane Hwy, Wethersfield, CT 06109

Open in the dashboard

General payments

$11,653

440 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brandon Tibbitts of Wethersfield, CT is reported in the CMS Open Payments database as having received $11,653 across 440 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,134 38
2024 General $1,159 35
2023 General $1,587 42
2022 General $4,201 157
2021 General $3,573 168

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandon Tibbitts
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Brandon Tibbitts were reported at $1,134. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Brandon Tibbitts Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,573 $132 $37–$438 $132
2022 $4,201 $155 $48–$522 $149
2023 $1,587 $167 $52–$557 $160
2024 $1,159 $178 $55–$600 $164
2025 $1,134 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,214 108 payments
  2. Amgen Inc. $1,575 33 payments
  3. Janssen Biotech, Inc. $1,364 54 payments
  4. Genzyme Corporation $1,073 34 payments
  5. Novartis Pharmaceuticals Corporation $887 46 payments
  6. UCB, Inc. $700 28 payments
  7. Lilly USA, LLC $608 19 payments
  8. Regeneron Healthcare Solutions, Inc. $561 25 payments
  9. Pfizer Inc. $493 20 payments
  10. Incyte Corporation $382 13 payments
  11. Other $1,796 60 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,305 436 payments
  2. Education $348 4 payments
Products named General payments · program years 2021–2025
  1. Otezla $1,481 32 payments
  2. TREMFYA $1,123 37 payments
  3. DUPIXENT Immunology $1,040 35 payments
  4. RINVOQ $935 35 payments
  5. COSENTYX $922 51 payments
  6. SKYRIZI $756 37 payments
  7. DUPIXENT Inflammation And Immunology $497 23 payments
  8. TALTZ $488 17 payments
  9. HUMIRA $462 33 payments
  10. EUCRISA $449 18 payments
  11. Other $5,212 211 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

491

Median for Physician Assistant: 241

Drug cost

$3,824

Median for Physician Assistant: $4,110

Branded share of claims

36.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Albuterol Sulfate Hfa Albuterol Sulfate Brand 66 $1,142
Doxycycline Monohydrate Generic 55 $561
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 76 $482
Cefdinir Generic 17 $226
Cephalexin Generic 32 $190
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 18 $182
Ofloxacin Generic 17 $143
Triamcinolone Acetonide Generic 12 $143
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 19 $141
Azithromycin Generic 38 $125

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$26,043

Medicare's payments for the services billed

Medicare patients

301

Average age 73

Services billed

562

168 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 46%
Ischemic heart disease 26%
Depression 26%
Diabetes 21%
Chronic kidney disease 20%
Atrial fibrillation 19%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
  • Amgen Inc. $194
$194 — —
Bimzelx
  • UCB, Inc. $162
$162 — —
TREMFYA
  • Janssen Biotech, Inc. $127
$127 — —
RINVOQ
  • AbbVie, Inc. $100
$100 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $85
$85 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

440 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record